ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2017, Vol. 26 ›› Issue (4): 381-385.

• 论文 • 上一篇    下一篇

活性维生素D及其类似物治疗血液透析患者继发性甲状旁腺功能亢进相关指南推荐

  

  • 出版日期:2017-08-28 发布日期:2017-09-04

Treatment of secondary hyperparathyroidism in hemodialysis patients with active vitamin D and its analogue—guidelines  review

  • Online:2017-08-28 Published:2017-09-04

摘要:

维生素D是钙、磷及骨代谢的重要调节激素,在血液透析患者中使用维生素D可上调维生素D受体,控制继发性甲状旁腺功能亢进(SHPT),纠正钙磷失衡。各国指南都推荐使用维生素D作为SHPT的重要治疗手段。但是,不合理的使用维生素D治疗,尤其是活性维生素D及类似物的过早或过量使用,可能增加体内钙磷负荷,心血管系统钙化及心血管事件的发病风险。因此,本文整理各国慢性肾脏病矿物质和骨异常(CKDMBD)指南中有关活性维生素D及其类似物治疗SHPT的内容,希望从发挥其有益的治疗作用,减少不良反应的角度,为临床医生治疗SHPT提供更多的参考。

Abstract:

Vitamin D (VD) is an essential hormone which is functional in adjustment of calcium and phosphorus homeostasis and bone metabolism. Treat hemodialysis patients with VD could exert meaningful effect on upregulating expressing of VD receptor, secondary hyperparathyroidism control and reversion of calcium and phosphorus homeostasis. But inappropriate VD treatment, especially early use and overdose treatment of active VD or its analogue also increases internal load of calcium and phosphorus, and the risk of cardiovascular calcification. So this review is trying to summarize detail recommendations and descriptions of VD treatment in CKD-MBD guidelines from multiple countries, standing on angle of benefit against side effect, wish to offer a handy reference to Chinese real clinical practice.